Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bionat2: Biomarkers for Natalizumab in MS
NCT00942214Phase 4Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jun 2009
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of natalizumab in multiple sclerosis (MS), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Haplotypic frequency difference between responders and non-responders at 24 months. Started Jun 2009; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00942214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942214.